The Gap Between a Meal Response and a Drug

The claim this article is about

A large amount of writing suggests that particular foods, fibres, eating patterns or supplements raise GLP-1 and therefore do something comparable to what the medicines do. The first half of that is often mechanistically correct: the sensors exist, the pathways are characterised, and several dietary components genuinely engage them. The second half does not follow, and the reasons are specific rather than a general scepticism about diet.

Duration is the largest difference

Native GLP-1 is destroyed within minutes by DPP-4, which cleaves it after the second residue. Secretion is therefore a series of short postprandial bursts separated by long intervals at baseline. Every clinical GLP-1 receptor agonist is engineered specifically to defeat this: the second residue is substituted or protected so DPP-4 cannot cleave it, and further engineering - fatty acid acylation for albumin binding, or fusion to a larger protein - extends persistence to days. A weekly agent produces continuous receptor occupancy for the whole week. No amount of stimulating secretion produces that, because the enzyme that ends the signal is still there and still working at the same rate.

Location is the second

Because native GLP-1 is degraded so quickly, much of what it does physiologically happens locally, on GLP-1 receptors on vagal afferent terminals near the site of release, with the message travelling onward as nerve traffic. A DPP-4-resistant agonist at continuous concentrations reaches receptors the hormone largely does not, including central sites. So the two are not the same signal at different volumes; they engage overlapping but distinct parts of the system.

The result that makes the point hardest to argue with

Krieger and colleagues knocked down GLP-1 receptors on vagal afferent neurons in rats. Meal size increased, gastric emptying accelerated, postmeal glycaemia rose and insulin release was blunted - so the receptors were doing real physiological work. But the authors report that full expression of those receptors is not necessary for the maintenance of long-term energy balance under normal eating conditions. Removing most of the receptors through which native GLP-1 acts did not change body weight over time. If the physiological pathway does not set body weight when it is taken away, amplifying it is not an obvious route to changing body weight either.

The commercial evidence points the same way

Stimulating endogenous secretion has been pursued seriously as a drug strategy for two decades. GPR119 agonists, FFAR1 agonists and TGR5 agonists have all been developed on precisely this reasoning, by companies with substantial resources and access to the same mechanisms described in this library. None has produced a licensed weight-management medicine. That is not proof that the approach cannot work, but it is a strong signal about the ceiling: secretagogues are bounded by how much hormone the cells can release and how fast DPP-4 removes it, and receptor agonists are not.

What can honestly be said

That the nutrient-sensing pathways are real and well characterised. That several dietary components engage them. That doing so produces measurable changes in postprandial GLP-1 in some studies. And that none of this has been shown to produce the effects that GLP-1 receptor agonists produce, which are the effects people usually have in mind when the comparison is made. Semaglutide, tirzepatide and orforglipron are licensed medicines prescribed and monitored by clinicians. Nothing supplied on this site is a version of any of them, an alternative to any of them, or a means of achieving what they achieve, and no article here should be read as suggesting otherwise.

Quick reference